☰

Delta Pharma Limited

Bridging legacy lines and biopharma expansion

Industry
Pharmaceuticals and Biopharmaceuticals
Headquarters
Dhaka, Bangladesh
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Delta Pharma Limited's published strategy and is not endorsed by, or produced in cooperation with, Delta Pharma Limited. Company website

Strategic priorities

Delta Pharma has committed approximately $100 million to the Narayanganj Special Economic Zone in Bangladesh for a biopharmaceutical fill-finish unit, an injectable oncology facility and an API plant, with first oncology production expected within three years. The 2023-2024 annual report shows assets in construction rising from BDT 449 million in 2021 to BDT 5,691 million in 2024 — about 37 percent of the balance sheet — alongside net profit crossing BDT 1 billion for the first time.

The expansion runs alongside a portfolio that still depends on lines installed in the 1990s. The Kutno-area factories mix older equipment whose data does not leave the controller with newer 2022 lines, and the company's own quality-control workflow is described in internal and partner analysis as paper-based, with results moved between devices and lab systems by USB stick.

In June 2024 the company launched the inQuiQ platform, a nanophotonic evanescent-field sensing instrument positioned for in-house R&D and external sale. The instrument is part of a stated shift from a regional generics producer to a TechBio organisation whose products sit across pharmaceuticals, biologics, oncology and research instrumentation.

The 2023-2024 annual report is published in accordance with the Global Reporting Initiative (GRI) Standards, and 100 percent of workers are covered by the occupational health and safety management system. Management has named digital awareness, MTP-based modular manufacturing, and integrated Laboratory Execution Systems (LES) as the operational backbone for the next phase.

Challenges we see

  • Digital Integration

    Connecting older equipment to modern data systems

    Production environments mix 1990s-era equipment whose controllers were never designed to expose data with modern 2022 lines. Company materials describe the older assets as operating as data black boxes, while the newer lines are networked but not necessarily integrated into a shared model.

    Where each generation of equipment speaks to its own controller, the population available for process optimisation is the newest lines only. Bringing the older assets into the same data model extends that population to the whole plant, which is what cross-batch learning and predictive maintenance need to start with.

  • Compliance Regulatory

    Producing compliant audit trails across paper-based QC

    Quality control laboratories are described in internal and partner analysis as working largely on paper, with disconnected instruments and results transferred by USB stick rather than written through a controlled system. The company has named integrated LES and digital QC as a stated response, and is targeting GMP and FDA-aligned practice for its new biopharma and oncology lines.

    Once a QC result is keyed by hand from a printout, the chain from instrument to audit record is held together by the discipline of the person typing it. Capturing the result at the instrument puts the chain in the system, which is what an inspector asks to see and what a release decision can be traced back to.

  • Operations Manufacturing

    Moving from chemical synthesis to biologicals without losing batches

    The shift from chemical synthesis to biologicals introduces processes such as insulin biosimilar production, where small deviations in bioreactor parameters change yield and quality. Company and partner material describe the conventional testing-only approach as reactive and insufficient for the sensitivity of these processes.

    In a sensitive bioprocess the population of interest is the whole run, not the sample drawn at the end. Modelling the run as a digital twin and instrumenting it in real time narrows attention from the whole batch to the moment in the run where the deviation starts, which is what makes proactive intervention possible.

  • People Operations

    Closing the skill gap on lab and process automation

    The life-sciences industry is reported in partner analysis to face a 57 percent skill gap on lab automation and digital interfaces. Delta Pharma employs more than 2,000 people across sites that are about to take on bioprocess, oncology and instrument-platform work that none of them has done at this scale before.

    When the interface to a new instrument or process requires the operator to learn a vendor-specific workflow, the rollout time is set by the slowest learner. Interfaces that mirror how the work is already described, and procedural guidance layered onto the equipment itself, compress that time and keep the rollout on schedule.

  • Operations Manufacturing

    Adapting production lines to smaller and changing batches

    Demand patterns are moving toward smaller batch sizes and more frequent product changes, particularly in oncology and biosimilars. Conventional hardware-software integration on production lines is described in partner material as taking months, and an incident involving a packaging mix-up that led to a recall is documented in company history.

    On a line where every change needs custom integration, the time between products is set by the engineering team. A line built around MTP (Module Type Package) lets a module describe what it does in a standard way, so a new product is a configuration change rather than an integration project.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Making older equipment part of the plant data model

    1990s legacy equipment holds process values inside controllers that were never designed to publish them, so the newer 2022 lines and the older assets do not contribute to the same monitoring, analytics or maintenance picture.

    Layering an MQTT (a lightweight publish/subscribe messaging protocol) or OPC UA (Open Platform Communications Unified Architecture) gateway onto older controllers publishes the values they already hold in a documented, vendor-neutral form, and the plant model can read from the whole fleet instead of the newest portion.

    • Annual Report 2023-2024, Delta Pharma Limited
    • Deep Research Report, Delta Life Science, January 2026

  2. Putting QC results into a controlled, searchable record

    QC laboratories work largely on paper with results rekeyed from instruments, so the chain between an analytical measurement and its appearance in the batch file is held together by hand discipline and is hard to query after the fact.

    Capturing results at the instrument and writing them into a laboratory execution system with timestamps, user identity and a change log turns the chain into a queryable record, so an audit question is answered by the system rather than by reconstructing who typed what.

    • Deep Research Report, Delta Life Science, January 2026
    • Annual Report 2023-2024, Delta Pharma Limited

  3. Modelling the new bioprocess lines before they go live

    Insulin biosimilar and oncology processes are sensitive to small deviations, and the conventional approach of confirming quality after the run leaves no opportunity to intervene during it. The new NSEZ lines are still being designed and qualified.

    A bioprocess digital twin built from historical and literature data lets runs be simulated under parameter changes before the line is commissioned, and AI vision on foam and cell morphology gives the operators a signal that conventional probes do not produce.

    • Deep Research Report, Delta Life Science, January 2026
    • Annual Report 2023-2024, Delta Pharma Limited

  4. Reducing onboarding time for new lab and process tools

    A 57 percent skill gap across life-sciences automation means the time taken to get an operator productive on a new instrument or process interface is one of the limiting factors on rollout. The company has more than 2,000 employees and is about to add several new lines.

    Interfaces designed around how operators already describe the work, with step-by-step guidance layered onto the equipment at the point of use, shorten the path from first contact to competent operation and keep training time as a known input to the rollout schedule.

    • Annual Report 2023-2024, Delta Pharma Limited
    • Deep Research Report, Delta Life Science, January 2026

  5. Designing the new NSEZ facility for module-level change

    Production lines built with traditional hardware and software integration take months to reconfigure, which is at odds with the smaller batch sizes and faster changeovers that oncology and biosimilar production will demand from the new facility.

    Building the orchestration layer and module contracts to the MTP (Module Type Package) standard from the start means a new product, vendor or capacity module is added by configuration, and the next changeover does not start from a blank engineering task.

    • Deep Research Report, Delta Life Science, January 2026
    • Annual Report 2023-2024, Delta Pharma Limited

What we'd propose

  • Enterprise AI

    Connectivity layer for legacy and modern equipment

    We publish the process values that older controllers already hold through an MQTT or OPC UA gateway, and aggregate them with the data from newer lines into a single plant model so monitoring, analytics and maintenance read from the whole fleet rather than the newest portion.

    • Gateway overlay for older controllers

      Data out of legacy equipment

      Install a hardware gateway on each older controller that subscribes to the values it already computes and republishes them in a documented, vendor-neutral protocol, without modifying the controller logic or replacing the machine.

    • Unified plant data model

      One model across generations

      Define the entities — equipment, process parameter, batch, product — once, so a value coming from a 1990s line and a value coming from a 2022 line describe the same kind of thing and can be queried in the same way.

    • Operational dashboards and predictive maintenance

      Live visibility plus foresight

      Build dashboards that surface the unified view to operators and supervisors, and trigger maintenance attention from drift on parameters that historically precede failure on the older equipment classes.

    • Process monitoring, analytics and maintenance read from the whole fleet, not the newest portion.
    • Older equipment stays in service under the same data regime as newer lines, which protects the capital already in the ground.
    • Predictive attention is grounded in the specific failure patterns of the older equipment classes.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Digital quality control laboratory

    We connect QC instruments to a laboratory execution system so results are captured at source with timestamps, user identity and a change log, and the LES synchronises with the LIMS so a release decision is traced back to the analytical run that produced each number.

    • Instrument integration at the bench

      Results captured at the instrument

      Connect balances, HPLC systems and plate readers through vendor-agnostic edge gateways, so the result is captured with the instrument identity, the method version and the timestamp attached rather than read from a screen and typed into another system.

    • Laboratory execution system

      The run, recorded as it happens

      Implement an LES that records sample receipt, preparation, the analytical method as executed, and the result, with each step carrying user identity and a timestamp so the chain of custody is held by the system.

    • 21 CFR Part 11 audit trail and LIMS sync

      Electronic records that hold up under inspection

      Configure electronic signature, versioning and audit-trail handling to 21 CFR Part 11, the US rule on electronic records and signatures, and synchronise the LES with the LIMS in near real time so sample and result status are consistent across both.

    • Each transfer between instrument and record is replaced by a system write, removing the steps an inspector would otherwise have to verify by interview.
    • Release waits on the analytical result, not on the paperwork that follows it.
    • The same QC data set serves batch release, method validation and trending studies without re-keying.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Bioprocess digital twin and AI vision

    We build a digital twin of the planned bioreactor lines from historical and literature data, and instrument the runs with AI vision for foam and cell morphology, so a deviation is flagged against the batch that is still running rather than discovered after it.

    • Process digital twin

      Runs simulated before they are made

      Construct a model of the planned bioreactor processes from historical data and published parameters, and use it to explore parameter ranges and feed strategies before the physical line is commissioned.

    • Computer vision for foam and cell state

      Signals traditional sensors miss

      Deploy camera-based monitoring with machine learning models trained on foam height, cell density and morphology, so the operators see what is happening inside the vessel in near real time rather than waiting for the next offline sample.

    • Batch outcome prediction

      A forecast against the running batch

      Train predictive models on the accumulated batch history so the current run's trajectory can be compared with the trajectories that produced acceptable and failed outcomes, and intervention can be triggered earlier than the next scheduled sample would allow.

    • Process development cycles shorten because the parameter exploration is partly computational.
    • Deviations are seen against the run in progress, which is the only moment when intervention changes the outcome.
    • The same twin infrastructure supports insulin biosimilar and oncology lines once they come online.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    MTP architecture for the Narayanganj facility

    We design the new NSEZ facility around the MTP (Module Type Package) standard, with a vendor-agnostic orchestration layer and module-level data contracts, so adding, swapping or scaling production modules becomes a configuration change rather than an integration project.

    • MTP module library

      Reusable module automation packages

      Develop MTP-compliant automation packages for the bioreactor, fill-finish and auxiliary modules the facility will use, following VDI/VDE/NAMUR 2658 so the modules describe their capabilities in a standard form that the orchestration layer can read.

    • Process orchestration layer

      One control plane, many vendors

      Implement a vendor-agnostic orchestration platform that coordinates MTP modules from different suppliers, enabling modules to be added, removed or replaced without reprogramming the surrounding line.

    • Changeover protocols under MTP

      From changeover project to changeover routine

      Design the product changeover workflow so module configuration and line clearance happen within the orchestration layer, with each step logged for compliance, and the engineering effort moves from a project per change to a routine.

    • The next capacity addition or vendor change is a configuration task rather than an integration project.
    • Smaller oncology and biosimilar batches become economically viable because changeover time is no longer set by engineering availability.
    • The same architecture language can be applied to other Delta Pharma sites as they are upgraded.

    We've done this before

    See how we do Digital CDMO
  • Agents

    AI agents for biopharma regulatory documentation

    Narrow, reviewable agents that take the repetitive part of document work tied to the new biopharma and oncology lines: drafting validation summaries from instrument and system records, checking a document against its template before review, and finding every controlled document that a standards change affects. A named person approves each output.

    • First drafts from system records

      Validation summaries written from data

      Generate the first draft of an equipment qualification, process validation summary or change-control document directly from the underlying commissioning, calibration and batch records, so the author edits and judges rather than assembles.

    • Template and completeness check

      Gaps found before review

      Check a submitted document against its template and the site's own checklist, returning missing or inconsistent sections before the document enters the human review queue.

    • Change impact across the controlled document set

      Which documents a change touches

      When a standard, method or specification changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one of the change.

    • Document review queues move faster because documents arrive complete.
    • The scope of a standards change is established by search rather than by recollection.
    • Each output is traceable to the source records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Delta Pharma Limited's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Equipment to enterprise connectivity 30 → 85
Production environments mix 1990s controllers that do not publish data with 2022 lines that do. Connecting the older fleet to the same data regime as the newer one is what makes a plant-level view possible.
QC data management 35 → 80
QC is described as paper-based with results moved between instruments and records by hand. A controlled laboratory execution system with instrument-level capture is what aligns the practice with GMP and FDA expectations.
Bioprocess automation 40 → 85
The shift from chemical synthesis to biologicals raises the bar from confirming quality after a batch to controlling the process during it. The new NSEZ facility is the chance to set that standard on lines that are being designed now.
Workforce digital readiness 25 → 75
A 57 percent industry skill gap and a workforce of more than 2,000 means interface design and point-of-use guidance are part of the rollout strategy, not an afterthought once the equipment is installed.
Production line flexibility 35 → 80
The conventional line integration cycle is measured in months, which is at odds with the smaller batch sizes the oncology and biosimilar portfolio will need. MTP-based module design removes that ceiling.
Predictive process intelligence 20 → 75
Insulin biosimilar and oncology processes are sensitive to small deviations, so the difference between reactive testing and a running forecast on the batch is meaningful. The new lines are the right place to build that capability.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Delta Pharma Limited, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].